Can sodium-glucose co-transporter-2 (SGLT-2) inhibitor reduce the risk of adverse complications due to COVID-19? – Targeting hyperinflammation

References

• World Health Organization (WHO). Novel Coronavirus (2019nCoV) situation report – 52. Data as reported by 14 May 2020. Geneva (Switzerland): WHO; 2020 [cited 2010 May 14]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
   Google Scholar
• Sun X, Wang T, Cai D, et al. Cytokine storm intervention in the early stages of COVID-19 pneumonia. Cytokine Growth Factor Rev. 2020;53:38–42.
   PubMed Web of Science ®Google Scholar
• Aggarwal G, Cheruiyot I, Aggarwal S, et al. Association of cardiovascular disease with coronavirus disease 2019 (COVID-19) severity: a meta-analysis. Curr Probl Cardiol. 2020;45(8):100617.
   PubMed Web of Science ®Google Scholar
• Guzik TJ, Mohiddin SA, Dimarco A, et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020;116(10):1666–1687.
   PubMed Web of Science ®Google Scholar
• Barron E, Bakhai C, Kar P, et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole-population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822.
   PubMed Web of Science ®Google Scholar
• Prevention, C.f.D.C.a. People with certain medical conditions. [cited 2021 Apr 30]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-withmedical-conditions.html
   Google Scholar
• Long B, Brady WJ, Koyfman A, et al. Cardiovascular complications in COVID-19. Am J Emerg Med. 2020;38(7):1504–1507.
   PubMed Web of Science ®Google Scholar
• Li B, Yang J, Zhao F, et al. Prevalence and impact of cardiovascular metabolic diseases on COVID-19 in China. Clin Res Cardiol. 2020;109(5):531–538.
   PubMed Web of Science ®Google Scholar
• Dorsey-Trevino EG, González-González JG, Alvarez-Villalobos N, et al. Sodium-glucose cotransporter 2 (SGLT-2) inhibitors and microvascular outcomes in patients with type 2 diabetes: systematic review and meta-analysis. J Endocrinol Invest. 2020;43(3):289–304.
   PubMed Web of Science ®Google Scholar
• Kosiborod MN, Esterline R, Furtado RHM, et al. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Diabetes Endocrinol. 2021;9(9):586–594.
   PubMed Web of Science ®Google Scholar
• Channappanavar R, Perlman S. Pathogenic human coronavirus infections: causes and consequences of cytokine storm and immunopathology. Semin Immunopathol. 2017;39(5):529–539.
   PubMed Web of Science ®Google Scholar
• Chousterman BG, Swirski FK, Weber GF. Cytokine storm and sepsis disease pathogenesis. Semin Immunopathol. 2017;39(5):517–528.
   PubMed Web of Science ®Google Scholar
• Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet. 2020;395(10223):497–506.
   PubMed Web of Science ®Google Scholar
• Conti P, Ronconi G, Caraffa A, et al. Induction of pro-inflammatory cytokines (IL-1 and IL-6) and lung inflammation by coronavirus-19 (COVI-19 or SARS-CoV-2): anti-inflammatory strategies. J Biol Regul Homeost Agents. 2020;34(2):327–331.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. The Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Ruan Q, Yang K, Wang W, et al. Clinical predictors of mortality due to COVID-19 based on an analysis of data of 150 patients from Wuhan, China. Intensive Care Med. 2020;46(5):846–848.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.
   PubMed Web of Science ®Google Scholar
• Zhang W, Zhao Y, Zhang F, et al. The use of anti-inflammatory drugs in the treatment of people with severe coronavirus disease 2019 (COVID-19): the perspectives of clinical immunologists from China. Clinical Immunology, 2020;214:108393.
   PubMed Web of Science ®Google Scholar
• Xu Z, Shi L, Wang Y, et al. Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420–422.
   PubMed Web of Science ®Google Scholar
• Siddiqi HK, Mehra MR. COVID-19 illness in native and immunosuppressed states: a clinical-therapeutic staging proposal. J Heart Lung Transplant. 2020;39(5):405–407.
   PubMed Web of Science ®Google Scholar
• Guan W-J, Ni Z-Y, Hu Y, et al. Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. 2020;382(18):1708–1720.
   PubMed Web of Science ®Google Scholar
• Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese center for disease control and prevention. JAMA. 2020;323(13):1239–1242.
   PubMed Web of Science ®Google Scholar
• Yang J, Zheng Y, Gou X, et al. Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. Int J Infect Dis. 2020;94:91–95.
   PubMed Web of Science ®Google Scholar
• Onder G, Rezza G, Brusaferro S. Case-Fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. JAMA. 2020;323(18):1775–1776.
   PubMed Web of Science ®Google Scholar
• Wang D, Hu B, Hu C, et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020;323(11):1061–1069.
   PubMed Web of Science ®Google Scholar
• Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular considerations for patients, health care workers, and health systems during the COVID-19 pandemic. J Am Coll Cardiol. 2020;75(18):2352–2371.
   PubMed Web of Science ®Google Scholar
• Guo Y-R, Cao Q-D, Hong Z-S, et al. The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak - an update on the status. Mil Med Res. 2020;7(1):11.
   PubMed Web of Science ®Google Scholar
• Cherney DZI, Perkins BA, Soleymanlou N, et al. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2014;129(5):587–597.
   PubMed Web of Science ®Google Scholar
• Steven S, Oelze M, Hanf A, et al. The SGLT-2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 2017;13:370–385.
   PubMed Web of Science ®Google Scholar
• Li L, Konishi Y, Morikawa T, et al. Effect of a SGLT-2 inhibitor on the systemic and intrarenal renin-angiotensin system in subtotally nephrectomized rats. J Pharmacol Sci. 2018;137(2):220–223.
   PubMed Web of Science ®Google Scholar
• Kim SR, Lee S-G, Kim SH, et al. SGLT-2 inhibition modulates NLRP3 inflammasome activity via ketones and insulin in diabetes with cardiovascular disease. Nat Commun. 2020;11(1):1–11.
   PubMed Web of Science ®Google Scholar
• Ojima A, Matsui T, Nishino Y, et al. Empagliflozin, an inhibitor of Sodium-Glucose cotransporter 2 exerts anti-Inflammatory and antifibrotic effects on experimental diabetic nephropathy partly by suppressing AGEs-Receptor axis. Horm Metab Res. 2015;47(9):686–692.
   PubMed Web of Science ®Google Scholar
• Mohamed HE, Asker ME, Keshawy MM, et al. Inhibition of tumor necrosis factor-α enhanced the antifibrotic effect of empagliflozin in an animal model with renal insulin resistance. Mol Cell Biochem. 2020;466(1–2):45–54.
   PubMed Web of Science ®Google Scholar
• Han JH, Oh TJ, Lee G, et al. The beneficial effects of empagliflozin, an SGLT-2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia. 2017;60(2):364–376.
   PubMed Web of Science ®Google Scholar
• Vallon V, Gerasimova M, Rose MA, et al. SGLT-2 inhibitor empagliflozin reduces renal growth and albuminuria in proportion to hyperglycemia and prevents glomerular hyperfiltration in diabetic Akita mice. Am J Physiol Renal Physiol. 2014;306(2):F194–F204.
   PubMed Web of Science ®Google Scholar
• Ye Y, Bajaj M, Yang H-C, et al. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Cardiovasc Drugs Ther. 2017;31(2):119–132.
   PubMed Web of Science ®Google Scholar
• Terami N, Ogawa D, Tachibana H, et al. Long-term treatment with the sodium glucose cotransporter 2 inhibitor, dapagliflozin, ameliorates glucose homeostasis and diabetic nephropathy in db/db mice. PLoS One. 2014;9(6):e100777.
   PubMed Web of Science ®Google Scholar
• Alshnbari AS, O’Sullivan SE, Idris I. SGLT-2-inhibitors inhibit tumour necrosis factor-α and interferon-ϒ-stimulated secretion of IL-6 in human endothelial cells: a potential anti-inflammatory effect in European Association for the Study of Diabetes. 2019.
   Google Scholar
• Alshnbari RK, O’Sullivan I, Idris S. Canagliflozin inhibit tumour necrosis factor‐α and interferon‐υ‐stimulated secretion of IL‐6 in human umbilical vein endothelial cells (HUVECs): a potential anti‐inflammatory effect. Diabetic Med. 2021:P80.
   Web of Science ®Google Scholar
• Yaribeygi H, Butler AE, Atkin SL, et al. Sodium-glucose cotransporter 2 inhibitors and inflammation in chronic kidney disease: possible molecular pathways. J Cell Physiol. 2018;234(1):223–230.
   PubMed Web of Science ®Google Scholar
• Ansary TM, Nakano D, Nishiyama A. Diuretic effects of sodium glucose cotransporter 2 inhibitors and their influence on the renin-angiotensin system. Int J Mol Sci. 2019;20(3):629.
   PubMed Web of Science ®Google Scholar
• Shin SJ, Chung S, Kim SJ, et al. Effect of sodium-glucose co-transporter 2 inhibitor, dapagliflozin, on renal renin-angiotensin system in an animal model of type 2 diabetes. PLoS One. 2016;11(11):e0165703.
   PubMed Web of Science ®Google Scholar
• Subasinghe AK, Wark JD, Gorelik A, et al. The association between inflammation, obesity and elevated blood pressure in 16–25-year-old females. J Hum Hypertens. 2017;31(9):580–584.
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Nagashimada M, et al. SGLT-2 inhibition by empagliflozin promotes fat utilization and browning and attenuates inflammation and insulin resistance by polarizing M2 macrophages in diet-induced obese mice. EBioMedicine. 2017;20:137–149.
   PubMed Web of Science ®Google Scholar
• Xu L, Nagata N, Chen G, et al. Empagliflozin reverses obesity and insulin resistance through fat browning and alternative macrophage activation in mice fed a high-fat diet. BMJ Open Diabetes Res Care. 2019;7(1):e000783.
   PubMed Web of Science ®Google Scholar
• Naznin F, Sakoda H, Okada T, et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur J Pharmacol. 2017;794:37–44.
   PubMed Web of Science ®Google Scholar
• Mora‐Gutiérrez JM, et al. Arterial spin labeling MRI is able to detect early hemodynamic changes in diabetic nephropathy. J Magn Reson Imaging. 2017;46(6):1810–1817.
   PubMed Web of Science ®Google Scholar
• Jafar N, Edriss H, Nugent K. The effect of short-term hyperglycemia on the innate immune system. Am J Med Sci. 2016;351(2):201–211.
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Overview of the IL-1 family in innate inflammation and acquired immunity. Immunol Rev. 2018;281(1):8–27.
   PubMed Web of Science ®Google Scholar
• Groslambert M, Py BF. Spotlight on the NLRP3 inflammasome pathway. J Inflamm Res. 2018;11:359–374.
   PubMed Web of Science ®Google Scholar
• Segovia JA, Chang T-H, Winter VT, et al. NLRP3 is a critical regulator of inflammation and innate immune cell response during Mycoplasma pneumoniae infection. Infect Immun. 2017;86(1):e00548.
   PubMed Web of Science ®Google Scholar
• Oelze M, Kröller-Schön S, Welschof P, et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 2014;9(11):e112394.
   PubMed Web of Science ®Google Scholar
• Tahara A, Kurosaki E, Yokono M, et al. Effects of sodium-glucose cotransporter 2 selective inhibitor ipragliflozin on hyperglycaemia, oxidative stress, inflammation and liver injury in streptozotocin-induced type 1 diabetic rats. J Pharm Pharmacol. 2014;66(7):975–987.
   PubMed Web of Science ®Google Scholar
• Garvey WT, Van Gaal L, Leiter LA, et al. Effects of canagliflozin versus glimepiride on adipokines and inflammatory biomarkers in type 2 diabetes. Metabolism. 2018;85:32–37.
   PubMed Web of Science ®Google Scholar
• Tan SA, Tan L. Empagliflozin and canagliflozin attenuate inflammatory cytokines interferon-λ, tumor necrosis factor-α, interleukin-6: possible mechanism of decreasing cardiovascular risk in diabetes mellitus. J Am Coll Cardiol. 2018;71(11):A1830.
   Web of Science ®Google Scholar
• Iannantuoni F, et al. Empagliflozin ameliorates leukocyte–endothelium cell interactions and inflammation in type 2 diabetic patients. 2020.
   Google Scholar
• Vitale RJ, Valtis YK, McDonnell ME, et al. Euglycemic diabetic ketoacidosis with COVID-19 infection in patients with type 2 diabetes taking SGLT-2 inhibitors. AACE Clin Case Rep. 2021;7(1):10–13.
   PubMedGoogle Scholar
• Cure E, Cumhur Cure M. Can dapagliflozin have a protective effect against COVID-19 infection? A hypothesis. Diabetes Metab Syndr. 2020;14(4):405–406.
   PubMed Web of Science ®Google Scholar
• Ceriello A, Standl E, Catrinoiu D, et al. Issues of cardiovascular risk management in people with diabetes in the COVID-19 era. Diabetes Care. 2020;43(7):1427–1432.
   PubMed Web of Science ®Google Scholar
• Lopes RD, Macedo AVS, de Barros E Silva PGM, et al. Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-the BRACE CORONA trial. Am Heart J. 2020;226:49–59.
   PubMed Web of Science ®Google Scholar
• Kim MK, Jeon JH, Kim SW, et al. The clinical characteristics and outcomes of patients with moderate-to-Severe coronavirus disease 2019 infection and diabetes in Daegu, South Korea. Diabetes Metab J. 2020;44(4):602–613.
   PubMed Web of Science ®Google Scholar
• Izzi-Engbeaya C, Distaso W, Amin A, et al. Severe COVID-19 and diabetes - a retrospective cohort study from three London teaching hospitals. medRxiv. 2020.
   Google Scholar
• Dalan R, Ang LW, Tan WYT, et al. The association of hypertension and diabetes pharmacotherapy with COVID-19 severity and immune signatures: an observational study. Eur Heart J Cardiovasc Pharmacother. 2021;7(3):e48–e51.
   PubMed Web of Science ®Google Scholar
• Khunti K, Knighton P, Zaccardi F, et al. Prescription of glucose-lowering therapies and risk of COVID-19 mortality in people with type 2 diabetes: a nationwide observational study in England. Lancet Diabetes Endocrinol. 2021;9(5):293–303.
   PubMed Web of Science ®Google Scholar
• Israelsen SB, Pottegård A, Sandholdt H, et al. Comparable COVID-19 outcomes with current use of GLP-1 receptor agonists, DPP-4 inhibitors or SGLT-2 inhibitors among patients with diabetes who tested positive for SARS-CoV-2. Diabetes Obes Metab. 2021;23(6):1397–1401.
   PubMed Web of Science ®Google Scholar